Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naltrexone + paroxetine is a combination of two approved pharmaceutical drugs, naltrexone and paroxetine. Naltrexone is an opioid receptor antagonist primarily used to treat opioid use disorder and alcohol use disorder by blocking the euphoric and sedative effects of opioids and reducing cravings[6][7]. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used for major depressive disorder, anxiety disorders, obsessive-compulsive disorder, posttraumatic stress disorder, vasomotor symptoms of menopause, and premenstrual dysphoric disorder[3]. The combination has been studied in clinical settings for augmentation in treatment-refractory depression[2] as well as for compulsive sexual behavior disorder (CSBD)[9]. The rationale behind this combination lies in targeting both serotonergic pathways (via paroxetine) and the endogenous opioid system (via naltrexone), potentially providing synergistic effects in certain psychiatric or behavioral conditions. However, there are potential risks such as increased risk of serotonin syndrome when these drugs are combined[3], so their concomitant use should be closely monitored.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naltrexone + paroxetine.